The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery.

Results from the EBCTCG meta-analysis of systemic treatment of early breast cancer by hormone, cytotoxic, or biologic therapy methods in randomized trials involving 144,939 women show a highly significant advantage of 5 years versus 1 to 2 years of tamoxifen with respect to the risk of recurrence [ 14 ].

also in 132,142 other papers